NK:IO / Imperial College London

Startup

NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours.
Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms


Get Involved with the Advanced Therapies Congress

 

To sponsor or exhibit


Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

 

To speak


Ila Dickinson
ila.dickinson@terrapinn.com
+44 207 092 1150